Last updated on April 2016

A Phase 3, Randomized, Double-Blind, Placebo-controlled Study of LY2951742 in Patients with Episodic Migraine


Brief description of study

A Phase 3, Randomized, Double-Blind, Placebo-controlled Study of LY2951742 in Patients with Episodic Migraine

Detailed Study Description

To assess the efficacy and safety of two doses of LY2951742 in the prevention of migraine headache compared with placebo in patients suffering from episodic migraine. Episodic migraine is defined as 4-14 migraine headache days (with or without aura) per month.

Clinical Study Identifier: TX143172

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.